Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.25
THRX's Cash to Debt is ranked lower than
93% of the 831 Companies
in the Global Biotechnology industry.

( Industry Median: 56.93 vs. THRX: 0.25 )
Ranked among companies with meaningful Cash to Debt only.
THRX' s 10-Year Cash to Debt Range
Min: 0.25   Max: N/A
Current: 0.25

Equity to Asset -0.53
THRX's Equity to Asset is ranked lower than
96% of the 599 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. THRX: -0.53 )
Ranked among companies with meaningful Equity to Asset only.
THRX' s 10-Year Equity to Asset Range
Min: -1.04   Max: 0.67
Current: -0.53

-1.04
0.67
F-Score: 4
Z-Score: -2.75
M-Score: 474.64
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -114.60
THRX's Operating margin (%) is ranked lower than
55% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -76.18 vs. THRX: -114.60 )
Ranked among companies with meaningful Operating margin (%) only.
THRX' s 10-Year Operating margin (%) Range
Min: -53258.33   Max: -9.58
Current: -114.6

-53258.33
-9.58
Net-margin (%) -691.71
THRX's Net-margin (%) is ranked lower than
76% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. THRX: -691.71 )
Ranked among companies with meaningful Net-margin (%) only.
THRX' s 10-Year Net-margin (%) Range
Min: -50786.54   Max: -13.66
Current: -691.71

-50786.54
-13.66
ROE (%) -444.65
THRX's ROE (%) is ranked lower than
97% of the 755 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. THRX: -444.65 )
Ranked among companies with meaningful ROE (%) only.
THRX' s 10-Year ROE (%) Range
Min: -444.65   Max: -54.55
Current: -444.65

-444.65
-54.55
ROA (%) -20.08
THRX's ROA (%) is ranked higher than
52% of the 835 Companies
in the Global Biotechnology industry.

( Industry Median: -23.43 vs. THRX: -20.08 )
Ranked among companies with meaningful ROA (%) only.
THRX' s 10-Year ROA (%) Range
Min: -82.22   Max: -5.91
Current: -20.08

-82.22
-5.91
ROC (Joel Greenblatt) (%) -34.73
THRX's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -353.07 vs. THRX: -34.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
THRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1267.07   Max: -133.15
Current: -34.73

-1267.07
-133.15
Revenue Growth (3Y)(%) -35.60
THRX's Revenue Growth (3Y)(%) is ranked lower than
77% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. THRX: -35.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
THRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 125.7
Current: -35.6

0
125.7
EBITDA Growth (3Y)(%) -43.80
THRX's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. THRX: -43.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
THRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -63.2   Max: -2.8
Current: -43.8

-63.2
-2.8
EPS Growth (3Y)(%) -22.40
THRX's EPS Growth (3Y)(%) is ranked lower than
69% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. THRX: -22.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
THRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -47.1   Max: -2.7
Current: -22.4

-47.1
-2.7
» THRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

THRX Guru Trades in Q2 2014

Richard Perry 1,517,208 sh (New)
First Eagle Investment 1,595,520 sh (unchged)
Jeremy Grantham Sold Out
Jim Simons Sold Out
Seth Klarman 20,395,056 sh (-1.50%)
Chuck Royce 4,300 sh (-81.22%)
» More
Q3 2014

THRX Guru Trades in Q3 2014

Richard Perry 1,831,099 sh (+20.69%)
Chuck Royce Sold Out
First Eagle Investment 1,593,620 sh (-0.12%)
Seth Klarman 19,815,983 sh (-2.84%)
» More
Q4 2014

THRX Guru Trades in Q4 2014

Richard Perry 4,026,736 sh (+119.91%)
Seth Klarman 21,753,460 sh (+9.78%)
Seth Klarman 19,815,983 sh (unchged)
First Eagle Investment 1,593,620 sh (unchged)
» More
Q1 2015

THRX Guru Trades in Q1 2015

Joel Greenblatt 52,837 sh (New)
First Eagle Investment 1,680,910 sh (+5.48%)
Seth Klarman 19,815,983 sh (unchged)
Richard Perry 4,026,736 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with THRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 23.15
THRX's Forward P/E is ranked lower than
53% of the 308 Companies
in the Global Biotechnology industry.

( Industry Median: 21.19 vs. THRX: 23.15 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/S 118.82
THRX's P/S is ranked lower than
89% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 12.45 vs. THRX: 118.82 )
Ranked among companies with meaningful P/S only.
THRX' s 10-Year P/S Range
Min: 8.87   Max: 3040
Current: 118.82

8.87
3040
Current Ratio 23.90
THRX's Current Ratio is ranked higher than
92% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. THRX: 23.90 )
Ranked among companies with meaningful Current Ratio only.
THRX' s 10-Year Current Ratio Range
Min: 2.41   Max: 23.9
Current: 23.9

2.41
23.9
Quick Ratio 23.90
THRX's Quick Ratio is ranked higher than
92% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: 4.16 vs. THRX: 23.90 )
Ranked among companies with meaningful Quick Ratio only.
THRX' s 10-Year Quick Ratio Range
Min: 2.41   Max: 23.9
Current: 23.9

2.41
23.9
Days Sales Outstanding 232.00
THRX's Days Sales Outstanding is ranked lower than
91% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 61.96 vs. THRX: 232.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
THRX' s 10-Year Days Sales Outstanding Range
Min: 2.86   Max: 3530.67
Current: 232

2.86
3530.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.44
THRX's Dividend Yield is ranked higher than
93% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 0.87 vs. THRX: 4.44 )
Ranked among companies with meaningful Dividend Yield only.
THRX' s 10-Year Dividend Yield Range
Min: 1.19   Max: 4.94
Current: 4.44

1.19
4.94
Yield on cost (5-Year) 4.40
THRX's Yield on cost (5-Year) is ranked higher than
89% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.36 vs. THRX: 4.40 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
THRX' s 10-Year Yield on cost (5-Year) Range
Min: 1.19   Max: 4.94
Current: 4.4

1.19
4.94
Share Buyback Rate -10.90
THRX's Share Buyback Rate is ranked higher than
50% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. THRX: -10.90 )
Ranked among companies with meaningful Share Buyback Rate only.
THRX' s 10-Year Share Buyback Rate Range
Min: -2.2   Max: -105.4
Current: -10.9

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 2.00
THRX's Price/Median PS Value is ranked lower than
66% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. THRX: 2.00 )
Ranked among companies with meaningful Price/Median PS Value only.
THRX' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 49.63
Current: 2

0.16
49.63
Earnings Yield (Greenblatt) -0.70
THRX's Earnings Yield (Greenblatt) is ranked higher than
74% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.60 vs. THRX: -0.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
THRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -9.6   Max: 0
Current: -0.7

-9.6
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HVE.Germany,
Theravance Inc., was incorporated in Delaware in November 1996 under the name Advanced Medicine, Inc. and began operations in May 1997. The Company changed its name to Theravance, Inc. in April 2002.is a biopharmaceutical company with a pipeline of internally discovered product candidates and collaborations with pharmaceutical companies. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Its key programs include: RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, "FF/VI"), ANORO ELLIPTA (umeclidinium bromide/vilanterol, "UMEC/VI") and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with Glaxo Group Limited (GSK), and its Long-Acting Muscarinic Antagonist program. Its drug discovery efforts are based on the principles of multivalency. Multivalency refers to the simultaneous attachment of a single molecule to multiple binding sites on one or more biological targets. When compared to monovalency, whereby a molecule attaches to only one binding site, multivalency can significantly increase a compound's potency, duration of action and/or selectivity. Multivalent compounds generally consist of several individual small molecules, at least one of which is biologically active when bound to its target, joined by linking components. The Company has limited in-house active pharmaceutical ingredient (API) production capabilities, and rely primarily on a number of third parties, including contract manufacturing organizations and collaborative partners, to produce active pharmaceutical ingredient and drug product. The development and commercialization of VIBATIV and its product candidates and ongoing research are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for THRX

Headlines

Articles On GuruFocus.com
Insiders' New Buys : MAC, SPB, PDVW, HNSN, THRX, RSG, CVX May 18 2015 
Seth Klarman's Trades During Q1 2015 Apr 20 2015 
Richard Perry's Fourth-Quarter Transactions Had High Impact on Portfolio Feb 16 2015 
Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX Dec 05 2014 
Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung Function Compared to Tiotropium Oct 17 2014 
Theravance, Inc. Appoints Eric d'Esparbes as Senior Vice President and Chief Financial Officer Oct 15 2014 
Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
Seth Klarman's Top 5 Second Quarter Holdings Aug 14 2013 
Top Four from Baupost’s Seth Klarman Jul 18 2013 

More From Other Websites
Theravance Biopharma and SciClone Pharmaceuticals Enter Into Development and Commercialization... May 27 2015
SciClone Pharmaceuticals and Theravance Biopharma Enter Into Development and Commercialization... May 27 2015
THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits May 20 2015
Theravance Biopharma Presents Additional Positive Phase 2b Study Data on TD-4208 for Treatment of... May 20 2015
THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits May 18 2015
Theravance Biopharma Presents Positive Phase 2 Study Data on Velusetrag (TD-5108) for Treatment of... May 18 2015
THERAVANCE INC Financials May 15 2015
5 Stocks Insiders Love Right Now May 13 2015
10-Q for Theravance, Inc. May 10 2015
THERAVANCE INC Files SEC form 10-Q, Quarterly Report May 08 2015
General Releases May 07 2015
Theravance to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference May 07 2015
Theravance Inc Earnings Call scheduled for 5:00 pm ET today May 06 2015
THERAVANCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 06 2015
Theravance Reports First Quarter 2015 Financial Results May 06 2015
Q1 2015 Theravance Inc Earnings Release - After Market Close May 06 2015
Theravance Biopharma Announces New Employment Inducement Awards May 04 2015
U.S. FDA approves Glaxo, Theravance's Breo Ellipta asthma drug May 01 2015
THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Apr 30 2015
Theravance Biopharma to Present at the Bank of America Merrill Lynch 2015 Health Care Conference Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK